This Action aims at using innovative translational research to identify colorectal cancer biomarkers for personalized medicine that will improve screening, early detection and disease follow-up, and attain better tumor profiling, state-of-the-art functional characterization of genetic variants and new therapy approaches

Read more

  • Cooperation studies on inherited susceptibility to colorectal cancer
  • TRANSCOLONCAN Group
  • Graphic

Events

News

Using genetics to gauge colorectal cancer risk

Tuesday, 20 November 2018

Discoveries by a COST Action linking genetic make-up with the risk of colorectal cancer have been published in the British Journal of Cancer - reaching some 9 million scientists and resulting in the creation of a new COST network.

More about "Using genetics to gauge colorectal cancer risk"


COST is supported by the EU Framework Programme Horizon 2020